Sign In
Buy ABEO
Abeona Therapeutics Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.300 |
| EPS Surprise | 9.09% |
| Revenue estimate | 4.572M |
| Revenue actual | 8.72M |
| Revenue Surprise | 90.72% |
| Release date | Mar 17, 2026 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.340 |
| EPS Surprise | 2.86% |
| Revenue estimate | 4.425M |
| Revenue actual | 5.4M |
| Revenue Surprise | 22.05% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.100 |
| EPS Surprise | 62.96% |
| Revenue estimate | 5.647M |
| Revenue actual | - |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.390 |
| EPS actual | $1.71 |
| EPS Surprise | 538.46% |
| Revenue estimate | 6.523M |
| Revenue actual | 400K |
| Revenue Surprise | -93.87% |
Last 4 Quarters for Abeona Therapeutics
Below you can see how ABEO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $7.23 |
| EPS estimate | -$0.390 |
| EPS actual | $1.71 |
| EPS surprise | 538.46% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $6.26 |
| Aug 11, 2025 | $6.28 |
| Aug 12, 2025 | $6.38 |
| Aug 13, 2025 | $6.56 |
| Aug 14, 2025 | $7.23 |
| Aug 15, 2025 | $7.13 |
| Aug 18, 2025 | $6.91 |
| Aug 19, 2025 | $6.84 |
| Aug 20, 2025 | $7.00 |
| 4 days before | 15.50% |
| 4 days after | -3.18% |
| On release day | -1.38% |
| Change in period | 11.82% |
| Release date | Nov 12, 2025 |
| Price on release | $4.95 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.100 |
| EPS surprise | 62.96% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $4.19 |
| Nov 07, 2025 | $4.20 |
| Nov 10, 2025 | $4.23 |
| Nov 11, 2025 | $4.17 |
| Nov 12, 2025 | $4.95 |
| Nov 13, 2025 | $4.53 |
| Nov 14, 2025 | $4.45 |
| Nov 17, 2025 | $4.51 |
| Nov 18, 2025 | $4.48 |
| 4 days before | 18.21% |
| 4 days after | -9.55% |
| On release day | -8.54% |
| Change in period | 6.92% |
| Release date | Mar 17, 2026 |
| Price on release | $4.76 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.340 |
| EPS surprise | 2.86% |
| Date | Price |
|---|---|
| Mar 11, 2026 | $5.01 |
| Mar 12, 2026 | $4.96 |
| Mar 13, 2026 | $4.76 |
| Mar 16, 2026 | $4.95 |
| Mar 17, 2026 | $4.76 |
| Mar 18, 2026 | $4.55 |
| Mar 19, 2026 | $4.54 |
| Mar 20, 2026 | $4.45 |
| Mar 23, 2026 | $4.42 |
| 4 days before | -4.99% |
| 4 days after | -7.14% |
| On release day | -4.41% |
| Change in period | -11.78% |
| Release date | May 13, 2026 |
| Price on release | $5.71 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.300 |
| EPS surprise | 9.09% |
| Date | Price |
|---|---|
| May 07, 2026 | $5.77 |
| May 08, 2026 | $5.90 |
| May 11, 2026 | $5.86 |
| May 12, 2026 | $5.68 |
| May 13, 2026 | $5.71 |
| May 14, 2026 | $5.60 |
| May 15, 2026 | $5.49 |
| May 18, 2026 | $5.37 |
| May 19, 2026 | $5.12 |
| 4 days before | -1.04% |
| 4 days after | -10.33% |
| On release day | -1.93% |
| Change in period | -11.27% |
Abeona Therapeutics Earnings Call Transcript Summary of Q1 2026
Abeona reported strong early commercial momentum for ZEVASKYN following its December launch: 5 commercial patients treated to date (3 in Q1 2026) generating $8.7M in net product revenue for Q1. Six qualified treatment centers (QTCs) are active with one additional target planned this year; the company cites a near-term identified pool of >100 patients across QTCs and community physicians. Payer coverage is broad (95% of commercial lives with published policies), approvals are lengthy but manageable with no patient attrition or final denials to date. Manufacturing turnaround from biopsy to product is ~23–26 days and commercial manufacturing success has been high. Financials: Q1 net revenue $8.7M, cost of sales $2.7M, R&D $9.6M (includes $7M upfront licensing fee), SG&A $19.5M, net loss $17.1M; cash and equivalents $168.3M. Abeona in‑licensed ABO‑701 (PSMA‑SIR‑T), a novel engineered T‑cell therapy targeting PSMA for advanced prostate cancer; pre‑IND meeting scheduled June 3, 2026, with IND/first‑in‑human expected H2 2027. Management is prioritizing commercial execution of ZEVASKYN while advancing PSMA program largely via external CDMO support and limited near‑term spend. They expect gross‑to‑net to normalize to mid‑ to upper‑teens and maintain that, depending on biopsy/treatment cadence, monthly profitability could be achievable as soon as June 2026.
